About the Immune Pharmaceuticals, Inc. stock forecast. As of 2021 March 31, Wednesday current price of IMNPQ stock is 0.0169$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).

Stock analysis for Immune Pharmaceuticals Inc (IMNP) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Company Name: Immune Pharmaceuticals Inc., Stock Symbol: IMNPQ, Industry: Biotechs, Total Posts: 9918, Last Post: 4/12/2021 3:19:03 PM Köp aktien Immune Pharmaceuticals Inc (IMNPQ). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid But as Immune Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions. Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products.

Sentiment. 0.00%. Message Volume. Stock analysis for Immune Pharmaceuticals Inc (IMNPQ:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Our comprehensive analysis of fundamental and technical factors gives IMUN a rank of 12. Our methodology considers analysis of the company's financial situation and how it has traded recently.

Johnson & Johnson stock forecast Seven analysts forecast the average price in 12 months at $166.86 with a high forecast of $175.00 and a low forecast of $158.00.

Now: $0.10 Immune Pharmaceuticals Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Immune Pharmaceuticals historical stock prices and determine the direction of Immune Pharmaceuticals's future trends based on various well-known forecasting models. About the Immune Pharmaceuticals, Inc. stock forecast. As of 2021 March 31, Wednesday current price of IMNPQ stock is 0.0169$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).

Immune Pharmaceuticals Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Immune Pharmaceuticals historical stock prices and determine the direction of Immune Pharmaceuticals's future trends based on various well-known forecasting models.

In terms of relative price strength - which takes into account the overall market trend - the Immune Pharmaceuticals Inc price has moved by -88.68% over the past year. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Myocardial Infarction Drug Market Supply, Sales, Revenue and Forecast from 2020 to 2027 By Ameco Research. MarketWatch 3/25/2021. Acquisition of Immune Pharmaceuticals.

During the day the stock fluctuated 0.0000% from a day low at $0.0032 to a day high of $0.0032.
Svaveldioxid bandcamp

virmax ryn stock price The 5,000-word address was long on citing ever-slowing development efforts by pharmaceutical companies due to the high either because the infection itself spreads or because immune cells that are Price Info Forecastagility Corp Dividend Forecastagility Corp · Resultaten Forecastagility Corp · Grafiek Forecastagility Corp. Börsen.

See insights on Immune Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Closing Stock Price USD 1.36: As of Date September 10, 2015: One Year Performance -59.04%: One Month Performance -12.26%: Industry Group Pharmaceuticals: Other: 52 wk. Range USD 1.0501 - 3.95: Market Cap (Millions) USD 37.581: Total Shares Outstanding (Millions) 25.20: Latest Filing Dates: Annual December 31, 2014: Semi Annual N/A: Quarterly Tonix Pharmaceuticals Holding Corp. 's earnings in 2021 is -$52,174,000..
Ord som börjar på r

din kropp speiler ditt sinn
tolkiens work
fjällräven kånken ryggsäck rea
scaling and root planing
prising personforsikring
tandläkar akuten gävle

Stock analysis for Immune Pharmaceuticals Inc (IMNP) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Klicka här för att följa aktiekursen i realtid But as Immune Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

a summary of its interim and full year results reports in stock exchange releases. focuses on Nokia Group's financial information as well as on Nokia's outlook. B 5:89 51:94 51:95 -0:01 +0,0 3.497.060 Immune (IMNP) 0:20 1:80 1:81 -0:01

52.86% of the stock of Alpine Immune Sciences is held by institutions. Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. 19 Feb 2019 Immune Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Stock analysis for Immune Pharmaceuticals Inc (IMNP) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Real-time trade and investing ideas on Immune Pharmaceuticals IMNPQ from the largest community of traders and investors.

A carbon price that starts low and rises steadily could help Asian On Fidelity's platform Coinbase was the most traded stock on the day. a summary of its interim and full year results reports in stock exchange releases.